Optimization of time interval for the measurement of plasma lipids for cardiovascular disease risk assessment

被引:0
|
作者
Sampson, Maureen [1 ]
Wolska, Anna [2 ]
Zubiran, Rafael [2 ]
Cole, Justine [1 ,2 ]
Amar, Marcelo [2 ]
Remaley, Alan T. [2 ]
机构
[1] NIH, Dept Lab Med, Clin Ctr, Bethesda, MD USA
[2] NHLBI, Lipoprotein Metab Lab, Translat Vasc Med Branch, NIH, 10 Ctr Dr,Bldg 10 Rm, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
Cardiovascular disease; cholesterol; lipids; lipid testing; risk score; testing frequency; TASK-FORCE; AGE; ASSOCIATION; CHOLESTEROL; PREVENTION; GUIDELINES; SOCIETY;
D O I
10.1080/14737159.2024.2306127
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background Lipid testing for atherosclerotic cardiovascular disease (ASCVD) risk is often performed every 4-6 years, but we hypothesized that the optimum time interval may vary depending on baseline risk.Research Design and Methods Using lipid values and other risk factors from the National Health and Nutrition Examination Survey (NHANES) (n = 9,704), we calculated a 10-year risk score with the pooled-cohort equations. Future risk scores were predicted by increasing age and projecting systolic blood pressure (SBP) and lipid changes, using the mean-percentile age group change in NHANES for SBP (n = 17,329) and the Lifelines Cohort study for lipids (n = 133,540). The crossing of high and intermediate-risk thresholds were calculated by time to determine optimum intervals for lipid testing.Results Time to crossing risk thresholds depends on baseline risk, but the mean increase in the risk score plateaus at 1% per year for those with a baseline 10-year risk greater than 15%. Based on these findings, we recommend the following maximum time intervals for lipid testing: baseline risk < 15%: 5-years, 16%: 4-years, 17%: 3-years, 18%: 2-years, and 19%: <= 1-year.Conclusions Testing patients for lipids who have a higher baseline risk more often could identify high-risk patients sooner, allowing for earlier and more effective therapeutic intervention.
引用
收藏
页码:123 / 133
页数:11
相关论文
共 50 条
  • [1] Apo CIII Proteoforms, Plasma Lipids, and Cardiovascular Risk in MESA
    Sinari, Shripad
    Koska, Juraj
    Hu, Yueming
    Furtado, Jeremy
    Jensen, Majken K.
    Budoff, Matthew J.
    Nedelkov, Dobrin
    McClelland, Robyn L.
    Billheimer, Dean
    Reaven, Peter
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2023, 43 (08) : 1560 - 1571
  • [2] microRNAs, Plasma Lipids, and Cardiovascular Disease
    Dávalos A.
    Fernández-Hernando C.
    Current Cardiovascular Risk Reports, 2011, 5 (1) : 10 - 17
  • [3] Using Polygenic Risk Scores for Prioritizing Individuals at Greatest Need of a Cardiovascular Disease Risk Assessment
    Chung, Ryan
    Xu, Zhe
    Arnold, Matthew
    Ip, Samantha
    Harrison, Hannah
    Barrett, Jessica
    Pennells, Lisa
    Kim, Lois G.
    Di Angelantonio, Emanuele
    Paige, Ellie
    Ritchie, Scott C.
    Inouye, Michael
    Usher-Smith, Juliet A.
    Wood, Angela M.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (15):
  • [4] Trajectories of Lipids Profile and Incident Cardiovascular Disease Risk: A Longitudinal Cohort Study
    Dayimu, Alimu
    Wang, Chunxia
    Li, Jiangbing
    Fan, Bingbing
    Ji, Xiaokang
    Zhang, Tao
    Xue, Fuzhong
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (21):
  • [5] Cardiovascular Risk, Lipids and Pregnancy: Preeclampsia and the Risk of Later Life Cardiovascular Disease
    Charlton, Francesca
    Tooher, Jane
    Rye, Kerry-Anne
    Hennessy, Annemarie
    HEART LUNG AND CIRCULATION, 2014, 23 (03) : 203 - 212
  • [6] Fasting or Non-fasting Lipids for Atherosclerotic Cardiovascular Disease Risk Assessment and Treatment?
    Rahman, Faisal
    Blumenthal, Roger S.
    Jones, Steven R.
    Martin, Seth S.
    Gluckman, Tyler J.
    Whelton, Seamus P.
    CURRENT ATHEROSCLEROSIS REPORTS, 2018, 20 (03)
  • [7] Fasting or Non-fasting Lipids for Atherosclerotic Cardiovascular Disease Risk Assessment and Treatment?
    Faisal Rahman
    Roger S. Blumenthal
    Steven R. Jones
    Seth S. Martin
    Tyler J. Gluckman
    Seamus P. Whelton
    Current Atherosclerosis Reports, 2018, 20
  • [8] Assessment of Lifetime Risk for Cardiovascular Disease: Time to Move Forward
    Sigala, Evangelia G.
    Panagiotakos, Demosthenes B.
    CURRENT CARDIOLOGY REVIEWS, 2024, 20 (06) : 18 - 33
  • [9] Assessment of cardiovascular disease risk in depressed women of reproductive and menopausal age
    Akhtar, Saima
    Afridi, M. Iqbal
    Bano, Samina
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 28 (06) : 2273 - 2278
  • [10] Assessment of Cardiovascular Disease Risk
    Goldsborough III, Earl
    Osuji, Ngozi
    Blaha, Michael J.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2022, 51 (03) : 483 - 509